Business Wire

Diligent Launches AI Act Toolkits to Support Organizations in Complying with New EU AI Regulation

18.9.2024 10:00:00 CEST | Business Wire | Press release

Share

Toolkits enable customers to identify AI systems, classify associated risk, ensure compliance with the EU's AI Act obligations and uphold global ethical best practices.

Diligent, a leading GRC SaaS company, today announced the launch of its new Artificial Intelligence (AI) Act Toolkits, designed to help corporate secretaries, legal and compliance teams, chief technology officers, chief information security officers and audit teams navigate the increasing complexity of AI governance and AI regulatory compliance. The Toolkits empower businesses operating inside and outside the European Union (EU) to understand and comply with the requirements of the EU's AI Act, and to integrate a responsible and ethical approach to AI adoption that builds trust in new technologies and adheres to global standards for AI governance.

“As the AI landscape evolves, organizations are challenged to balance innovation with regulatory compliance and ethical considerations,” said Keith Fenner, Senior Vice President & General Manager, International at Diligent. “The EU's AI Act represents a significant regulatory milestone to ensure AI systems are safe, transparent, and respect fundamental rights. We’re thrilled to offer a solution that helps customers identify and map regulatory obligations, implement best practice controls, and govern AI responsibly. This ensures compliance with evolving global regulations while accelerating the adoption of AI technology and delivering value.”

There are three toolkits available within the Diligent One Platform:

  • AI Discovery and Risk Classification Toolkit – This toolkit helps customers identify their AI systems and perform the required risk classification exercise. It also provides access to an extensive library of AI literacy and best practice governance resources for the board, senior management and employees to accelerate organizational readiness and elevate AI governance. The toolkit is available to all Diligent One Platform customers.
  • AI Act IT Compliance Toolkit – This toolkit helps organizations understand regulatory requirements, map them against suggested controls, and document compliance. It offers suggested control mapping to the AI Act’s regulatory requirements, gap identification, a dashboard summary for control assessment, a remediation summary and notifications to key stakeholders.
  • AI Act Risk Management Toolkit – This comprehensive risk management toolkit supports a complete AI governance program. It features a risk heatmap for reviewing and prioritizing risks, a dashboard summarizing AI systems by risk level, a pre-configured AI threat library, and tools for continuous monitoring to ensure policy adherence and compliance.

In a world where, according to surveys, 78% of employees bring their own AI tools to work and 86% of businesses use some form of AI without the board’s awareness, Diligent's AI Act Toolkits are designed to support compliance, governance and risk management efforts. The Toolkits help customers to identify their AI systems and models, apply a risk-based classification, understand their obligations as providers and deployers under the AI Act, build an AI governance framework and monitor ongoing compliance. This helps to ensure that AI systems are implemented responsibly and ethically, and in a manner that documents compliance efforts in accordance with customer, partner, employee and regulator expectations.

Diligent’s Toolkits provide a robust framework for assessing and managing the risks associated with AI systems, helping organizations incorporate ethical considerations into their AI development, and supporting ongoing compliance with the EU’s AI Act. As AI becomes increasingly integral to business strategy, the Toolkits reflect Diligent's dedication to supporting ethical AI practices and helping its customers stay ahead of regulatory changes.

To learn more about the AI Act Toolkits from Diligent, visit: https://www.diligent.com/lp/eu-ai-act-compliance

About Diligent

Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.

Follow Diligent on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918400561/en/

Contacts

Media

Media
Julia Stoyanov
Communications Director, Diligent  
+1 (604) 669-4225
Jhanbury@diligent.com

Jhanbury@diligent.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye